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Abstract
The mechanism of suberoylanilide hydroxamic acid in cell growth inhibition involved induction of
pRb-2/p130 interaction and nuclear translocation with E2F-4, followed by significant repression in
E2F-1 and PCNA nuclear levels, which led to inhibition in DNA synthesis in mammary epithelial cell lines.
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Synopsis
Background: Hybrid polar compounds (HPCs) have induced
cell growth arrest, terminal differentiation and/or apoptosis in
various transformed cell lines. We have previously reported that
the prototype HPC (hexamethylene bisacetamide [HMBA]) was
able to arrest the growth of transformed mammary (TM) 2H cells
(p53 null), a highly tumorigenic mouse mammary epithelial cell
line, by inhibiting G1 kinase activities, concomitant with an
increase in the cyclin D2 protein level and hypophosphorylated
isoforms of the three pRb pocket proteins, which led to the
formation of stable cyclin D2/pRb complexes and G1 cell arrest.
It has been reported that the second generation of HPCs
(suberoylanilide hydroxamic acid [SAHA]), structurally related to
but 2000-fold more potent than HMBA, was an inhibitor of
histone deacetylase activity and caused accumulation of
hyperacetylated histone H4 in murine erythroleukemia.
Objectives: To determine the mechanism of SAHA in cell
growth inhibition in TM10 (p53 wt) and TM2H (p53 null)
hyperplastic mouse mammary cell lines.
Methods: TM10 and TM2H cells were examined in the
presence or absence of 2.5mM SAHA for cell growth rate by
[3H]-thymidine uptake, DNA synthesis by flow cytometry after
cells were labeled with BrdU, G1/S cyclin-dependent kinase
(cdk) activities, phosphorylation levels of pRb pocket proteins,
protein levels of E2F-1, PCNA and p21, pRb-2/p130
interaction, and nuclear localization with E2F-4 by western blot,
immunoprecipitation and immunostaining assays.
Results: SAHA was able to arrest cell growth at G1, and
inhibited DNA synthesis in both TM10 and TM2H cell lines.
Cell growth arrest was accompanied by increases in histone
H3 and H4 protein and acetylation levels, a profound increase
in the interaction and nuclear localization of
pRb-2/p130–E2F-4 complexes, significant reductions in E2F-1
and PCNA protein levels, inhibition in G1/S cdk activities and
increases in the levels of hypophosphorylated isoforms of three
pRb pocket proteins.
Conclusion: A novel mechanism of SAHA mediated growth
inhibition through significant increases in the formation and
nuclear localization of pRb-2/p130–E2F-4 complexes, which
resulted in cell growth arrest and significant repression in the
levels of two key molecules, E2F-1 and PCNA, essential for
DNA synthesis in two mouse mammary epithelial cell lines.
These responses to SAHA were independent of the p53 status
of the cell; however, reversibility of SAHA-mediated growth
correlated with the wild type p53 status.
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Introduction
Progression through the mammalian cell cycle requires
that gene expression is coordinated with the activity of cell
cycle control proteins. A critical period is the transition
from the G1 into the S phase, as cells become committed
to the division cycle. Binding of free E2F/DP heterodimers
to E2F sites generally activates transcription of proteins
required for G1 ® S transition and DNA synthesis [1–5],
whereas complex formation with pRb or other pocket pro-
teins including p107 and pRb-2/p130 silences transcrip-
tional activities of downstream target genes [6–10]. The
resulting retinoblastoma protein (Rb)–E2F interaction not
only blocks transcriptional activation by E2F, but also
forms an active transcriptional repressor complex at the
promoter of cell cycle genes that can block transcription
by recruiting histone deacetylase (HDAC) and remodeling
chromatin [11–14].
Several HDAC inhibitors mediate cell growth arrest and/or
differentiation [15–17]. We chose to examine the effect of
HPCs, which have been reported to induce terminal differ-
entiation and/or apoptosis [18–20] in many transformed
cells. Although treatment with HMBA induces remission in
patients with myelodysplastic syndrome and acute myelo-
genoud leukemia, it is not currently used therapeutically
because of the high dosage required (millimolar blood
levels) and the accompanying toxic side effects (thrombo-
cytopenia) [21].
In this study, we report a novel mechanism of cell growth
inhibition by the second generation of HPCs, named
SAHA, which is 2000-fold more potent than HMBA and
bears at least one hydroxamide in place of the amides in
HMBA [17]. SAHA was reported to be a histone deacety-
lase inhibitor and caused accumulation of hyperacetylated
histone H4 in murine erythroleukemia [17]. Very little is
known about the anticancer mechanism of SAHA in
epithelial cells; however, a recent study demonstrated that
SAHA diet, at 900 parts per million (ppm), fed to rats
reduced methylenitrosouren-induced mammary tumor inci-
dence by 40%, total tumors by 66% and tumor volume by
78% [22]. In this study, we tested whether SAHA has
similar potency to inhibit cell growth in two mouse
mammary epithelial cell lines, TM10 (p53 wt) and TM2H
(p53 null). We identified a novel mechanism for SAHA in
cell growth arrest through inhibition in DNA synthesis,
concomitant with significant increases in the nuclear local-
ization of pRb-2/p130 associated with E2F-4, decreases
in key molecules in DNA synthesis (E2F-1, PCNA and
p21), and increases in histone H3 and H4 protein and
acetylation levels. This study discusses the difference in
recovery from cell growth inhibition in two mammary
epithelial cell lines, TM10 and TM2H, after SAHA removal
from cultures.
Materials and methods
Development of cell lines and cell culture
The TM10 and TM2H cell lines chosen for this study
were isolated from two different mouse mammary hyper-
plastic outgrowths: TM10 and TM2H, respectively, as
described earlier [23]. The parental TM10 outgrowth is
a moderately tumorigenic outgrowth line in vivo (time for
50% of the transplants to produce tumors, 11 months)
that is karyotypically diploid and maintains wild type p53
expression. TM2H, in contrast, is a highly tumorigenic
outgrowth line in vivo (time for 50% of the transplants
to produce tumors, £4 months), karyotypically aneu-
ploid (DNA index=1.69) and contains a p53 mutation
resulting in a null phenotype [24]. Exponentially growing
TM10 and TM2H cell lines in DMEM/F12 media
buffered with 10mM HEPES at pH 7.6 with 2% adult
bovine serum, 10mg/ml insulin, 5ng/ml epidermal
growth factor (EGF) and 5mg/ml gentamycin at
60–70% confluence were treated with SAHA (courtesy
of Dr Paul Marks and Dr Victoria Richon, Memorial
Sloan Kettering Cancer Center, New York, NY, USA).
Cells were examined at the time points indicated for cell
growth and cell cycle activities.
Analysis of cell growth
Cell growth rates of TM10 and TM2H lines were deter-
mined using a [3H]-thymidine uptake assay, as described
earlier [25]. In initial studies, both cell lines were cultured
in the absence or presence of 0.1, 2.5, 5.0, and 10mM
SAHA for 6 days. Both cell lines were also cultured for
2 days in the presence of SAHA at the concentrations
already mentioned, followed by removing SAHA from the
media for a subsequent 4 days. Based on the results of
these studies, subsequent experiments examined asyn-
chronously growing TM10 and TM2H cell lines in the
presence or absence of 2.5mM SAHA for 24h.
FACS analysis
Exponentially growing cells at 60–70% confluence at
control or treated with 2.5mM SAHA for 24h were pulse-
labeled for 1h with 10mM BrdU (Sigma, St Louis, MO,
USA). The cell cultures were rinsed once with phosphate
buffered saline (PBS), trypsinized for 3 min and rinsed
three times with PBS. Cells were resuspended in 200ml
PBS and fixed in 5ml cold 70% ethanol overnight. Fixed
cells were counted and, generally, 4×106 cells were
transferred to 15ml polypropylene tubes, centrifuged at
3000 rpm for 5 min and the supernatant removed. Cells
were stained for the newly incorporated BrdU for DNA
synthesis using BrdU monoclonal antibodies conjugated
to fluorescein isothiocyanate (FITC) and stained with pro-
pidium iodide for DNA content following the protocol
described in Becton and Dickinson’s (San Diego, CA,
USA) instructions for flow cytometric analysis.
Full articleNuclear and cytoplasmic extracts
To obtain nuclei, (4–6)×107 cells of each cell line grown
in the presence and absence of 2.5mM SAHA were
washed twice in PBS, followed by suspension in 0.3ml
nuclear buffer consisting of 2mM MgCl2, 5mM K2HPO4,
0.1mM EDTA, 1mM PMSF, 20mg/ml aprotinin, 20mg/ml
leupeptin, 0.1mM Na3VO4 and 5mM b-glycerophosphate.
An additional 0.3ml nuclear buffer containing 0.7% Triton
X-100 was then added, after standing on ice for
8–10 min. The suspensions were examined for cell lysis
microscopically, centrifuged at 800 rpm for 10 min at 4°C,
and the supernatant designated the cytoplasmic fraction.
The pellets were washed once with nuclear buffer, and the
nuclear extracts were prepared by resuspending the
pellets in 0.3ml buffer containing 20mM HEPES (pH 7.8),
25% glycerol, 0.42M NaCl, 1.5mM MgCl2, 0.2mM EDTA,
0.5mM PMSF, 0.5mM DTTl, 0.1mM Na3VO4, 50mM
NaF, 20mg/ml leupeptin, and 5mM b-glycerophosphate.
Sonication was carried out on ice using an ultrasonicator
processor (PGC Scientific, Caithersburg, MA, USA), and
the mixtures were examined microscopically for complete
break of the nuclei. The supernatants were designated as
nuclear extracts after centrifugation of the mixtures, and
the total protein was determined in the nuclear and cyto-
plasmic fractions.
Western blot and immunoprecipitation analysis
Histones were isolated and lyophilized from nuclear extracts
in SAHA treated and untreated TM10 and TM2H cell lines
following a protocol described earlier [26]. Histone samples
were assessed for purification quality on 15% SDS acry-
lamide gel including calf thymus histones as controls before
western blot analysis was carried out. Histone samples
were resolved by electrophoresis using 15% acid–urea gel
containing 36% w/v urea, 5% v/v acetic acid, 600ml
TEMED and 0.7ml of 10% ammonium persulfate prepared
as described elsewhere [27]. Gels were either stained by
Coomassie Brilliant Blue or equilibrated to be transferred
into transfer buffer (0.7% acetic acid). The gel sandwich
was set up as usual except for the placement of the blotting
membrane (because proteins in this type of gel will migrate
toward the negative electrode), and the procedure was con-
tinued as described earlier [27]. Each histone was resolved
into multiple bands and were visualized in Coomassie blue
gel. The acetylated histone isoforms were detected by
immunoblot against acetylated histone H3 isoforms using
anti-H3 antibodies raised and characterized by Dr Sharon
Roth at MD Anderson Cancer Center (personal communi-
cation) or against acetylated histone H4 isoforms using anti-
H4 polyclonal antibody (Upstate Biotechnology Inc, Lake
Placid, NY, USA).
Western blot analysis for all the proteins examined in this
study was carried out on equal amounts of cellular frac-
tion protein extracts (100mg/sample) following a proto-
col described earlier [25]. Staining the gel with
Coomassie Brilliant Blue for each experiment assessed
equal loading control. TM10 and TM2H cells (0.65×103
cells/cm2) seeded in 75 T flasks grew for 2 days, and
were treated with 2.5mM SAHA for 24h. Cellular frac-
tion protein extracts were prepared after SAHA treat-
ment [25]. Primary antibodies used at 1 or 2mg/ml were
p21/Cip (Pharmingen Inc, San Diego, CA, USA), pRb
(IF8), p107 (SD9), p130 (C-20), E2F-1 (C-20),
E2F-4(C-20) and PCNA (C-20) (Santa Cruz Biotechnol-
ogy Inc, Santa Cruz, CA, USA). All antibodies were
examined for specificity prior to use. The secondary
antibodies conjugated to horseradish peroxidase
(1:5000–1:15,000 dilution) were used followed by
enhanced chemiluminescence detection reaction as
described by the manufacturer (Amersham Pharmacia
Biotechnology, Amersham, Bucks, UK).
The immunoprecipitation assay followed by western blot
analysis was as described previously [25]. Briefly, equal
nuclear cell extract (200mg/sample) was mixed with 3mg
anti-E2F-4 antibodies at 4°C followed by the addition of
50ml protein A-sepharose beads (Amersham Biotechnol-
ogy). The immune complex was centrifuged, and the pro-
teins in the immune complex were resolved by 10%
SDS-PAGE followed by western blot analysis using anti-
pRb-2/p130 antibodies as already described for western
blot analysis.
Cyclin-dependent kinase assay
The TM10 and TM2H cell cultures at control and treated
with 2.5mM SAHA for 24h were examined for cyclin D1,
E, and A associated kinase activities as described previ-
ously [28]. Briefly, cellular protein extracts (25mg) were
precleared with 10ml of 10% preimmune normal rabbit
serum followed by immunoprecipitation with either 3mg
anti-cyclin D1, E polyclonal antibodies (Upstate Biotech-
nology), 2mg anti-cyclin A polyclonal antibody antibodies
(C-19)-G (Pharmingen), or normal rabbit preimmune
serum as a negative control. All antibodies were examined
for specificity [28]. Immunoprecipitate complexes were
examined for kinase assay following a procedure
described previously [28]. The substrates utilized in the
kinase assays were either Histone-H1 (Sigma) or RB
protein (Santa Cruz Biotechnology). The phosphorylated
H1 and pRb bands were scanned and quantitated densit-
ometrically using a Phosphoimager (Molecular Dynamics,
Sunnyvle, CA, USA).
Immunofluorescent staining
Exponentially growing cells on slides were fixed in 4%
paraformaldehyde in PEM buffer (80mM Pipes [pH 7.0],
5mM EGTA and 2mM MgCl2) for 30 min, permeabilized
in 0.5% Triton X-100 in PEM buffer at room temperature
for 15 min and rinsed three times with TBS + 0.1%
Tween 20, followed by incubation in 0.5% nonfat dry milk
in TBS + 0.1% Tween 20 for 2h at room temperature.
Breast Cancer Research    Vol 3 No 2 Said et alFor BrdU and DAPI double immunostaining, cells were
incubated for 30 min in media supplemented with 5mM
BrdU. After 30 min, cells were incubated in 2N HCl for
5 min at room temperature prior to incubation with the
primary antibody (this step was omitted for pRb-2/p130
immunostaining). Following washing three times, cells
were incubated in a (1:50) dilution of mouse anti-BrdU
monoclonal antibody (Boehringer Mannheim, Indianapo-
lis, IN, USA) for 2h at 37°C. After washing three times,
cells were then incubated in FITC-conjugated anti-mouse
secondary antibody (1:400) dilution for 1h at 37°C, fol-
lowed by washing three times with anti-fade equilibrating
buffer and mounting in anti-fade mounting medium (Mole-
cular Probe, Eugene, OR, USA). The same sequential
steps were followed for pRb-2/p130 immunostaining
using anti-pRb-2/p130 monoclonal antibodies (Santa
Cruz Biotechnology).
Apoptosis
Apoptotic activities in TM10 and TM2H cells in the
absence and presence of 2.5mM SAHA were examined
by two procedures: the TACS 2TdT In Situ Apoptosis
Detection assay following the manufacturer’s instructions
(Trevingen, Gaithersburg, MD, USA), and the DNA Frag-
mentation Assay described elsewhere [29].
Results
Effect of SAHA on TM10 and TM2H cell proliferation
and morphology
The TM10 and TM2H cell lines were used to investigate
whether the status of p53 influences the outcome of
SAHA treatment. The origin of TM10 and TM2H cell lines
was described earlier [30]. The rate of cell proliferation at
concentrations of 0, 1.0, 2.5, 5, and 10mM SAHA was
examined by [3H]-thymidine assay at the indicated time
points. The inhibitory effect of SAHA at concentrations of
2.5mM and higher on cell proliferation was profound on
both cell lines after 24h. The TM10 cell proliferation con-
tinued to be inhibited during the following 5 days in the
presence of SAHA, whereas minimal growth in TM2H cell
growth on days 3 and 4 was observed (Figs 1A,C). After
removing SAHA from the cultures following 2 days of
exposure to all SAHA concentrations, TM10 cells contin-
ued to be inhibited at concentrations of 2.5mM and higher
during the following 4 days of SAHA free cultures
(Fig. 1B), whereas TM2H cells resumed proliferation
(Fig. 1D). These results suggest that SAHA induced a
dose-dependent block in DNA replication on both cell
lines. A 2.5mM dose of SAHA was used in further experi-
ments because this concentration seems to be unequivo-
cally effective on cell growth inhibition on both cell lines
Available online http://breast-cancer-research.com/content/3/2/122
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Figure 1
Dose effect of SAHA on growth rate in TM10 and TM2H cell lines. (A), (C) Growth curves for TM10 and TM2H cell lines in the absence and
presence of 0, 0.1, 2.5, 5.0, and 10 mM SAHA. (B), (D) Growth curves in the absence and presence of the same SAHA concentrations as (A) and
(C) for 2 days, and then SAHA was removed from the media for the four following days. Each point is the average of four readings.after 24h of treatment. Furthermore, no apoptotic activity
was observed after 24 and 48h of treatment with 2.5mM
SAHA in both cell lines (data not shown).
The effect of SAHA on blocking cell proliferation through
blocking DNA synthesis was examined by BrdU labeling,
as determined by immunofluorescence staining (Fig. 2A),
and the cell cycle profile by flow cytometric analysis
(Fig. 2B). The BrdU indices in the control TM10 and
TM2H cells, including all types of BrdU staining patterns,
were 16 and 34%, respectively, indicating that the per-
centage of TM2H cells synthesizing DNA or in the ‘S
phase’ were more than double that of TM10 cells
(Fig. 2A). Upon 2.5mM SAHA treatment for 24h, 800 cells
per sample were counted stained with BrdU against cells
stained with DAPI, and BrdU labeling indices dropped
dramatically to 4 and 6% in TM10 and TM2H cells,
respectively. Furthermore, the BrdU staining revealed the
size and pattern of replication clusters, which are related
to the general patterns of DNA replication in mammalian
cell nuclei at early, mid and late S phase [31]. These data
suggested that 2.5mM SAHA was capable of inhibiting
cell proliferation in both TM10 and TM2H cell lines by
blocking DNA synthesis, regardless of their differences in
the number of cells synthesizing DNA.
These results were confirmed by flow cytometric analysis
after staining cells with BrdU for newly synthesized DNA
and with propidium iodide for DNA content. The percent-
ages of cells in the G1 and S phases in control TM10
cells at the time of treatment were 57 and 18%, respec-
tively, and those for TM2H cells were 39 and 28%,
respectively (Fig. 2B). The number of TM2H cells growth
arrested in the G1 phase upon SAHA treatment for 24h
increased by 21%, compared with the 8% increase in the
TM10 cell line, concomitant with similar differences in the
percentage of cells inhibited in the S and G2/M phases
(Fig. 2B). This difference in G1 cell growth arrest between
the two cell lines may be attributed to their differences in
the initial number of cells distributed in each cell cycle
phase before treatment.
The shape and morphology of TM10 and TM2H cells
grown on slides in the presence and absence of 2.5mM
SAHA were examined. The dimensions of 50 randomly
selected cells of each cell line were measured using a
microscope scale. The TM10 and TM2H mammary epithe-
lial cells measured 5.4±2.1 and 3.6±1.4mm in width and
13.7±5.9 and 18.6±8.0mm in length, respectively. TM10
cells generally had five to seven extensions, whereas
TM2H cells had three to five extensions. TM10 and TM2H
cells became flattened and increased in both nuclear and
cytoplasmic volume after 24h of 2.5mM SAHA treatment.
Both cells exhibited less distinct intracellular borders
(Fig. 3). The morphology of both cell lines was similar to
cells committed to cell differentiation; however, these
mammary cells grown on plastic dishes were unable to dif-
ferentiate by SAHA.
Effect of SAHA on histone protein and acetylation
levels in TM10 and TM2H cell lines
It is not known whether SAHA alters the protein acetyla-
tion levels of various histones in the mammary epithelial
cells. Changes in the acetylation or phosphorylation of his-
tones result in alterations that can be visualized as
changes in protein mobility on an acid–urea gel following
western blot analysis [26,27]. These gels separate his-
tones on the basis of charges as well as size, resulting in
multiple bands for each histone that correspond to differ-
ently modified isoforms. These isoforms can be identified
by their characteristic mobility and by staining with anti-
bodies specific to each histone isoform [26]. Protein and
acetylation levels of histone H3 and H4 isoforms on
histone samples isolated from SAHA treated and
untreated TM10 and TM2H cells stained by Coomassie
Brilliant Blue (Fig. 4A) and by western blots (Fig. 4B) were
examined to identify the potency of SAHA as a histone
deacetylase inhibitor on mammary epithelial cells. We
focused on H3 and H4 because antibodies are available
and acetylation events in those histones have been
Breast Cancer Research    Vol 3 No 2 Said et al
Figure 2
Effect of SAHA on cell growth properties of TM10 and TM2H
preneoplastic mammary cells. (A) BrdU immunostaining of TM10 and
TM2H cells at control or treated with 2.5 mM SAHA for 24 h. (B) Flow
cytometric analysis of TM10 and TM2H cell lines at the same
conditions as (A) were analyzed for BrdU fluorescence and DNA
content. Histograms of cell cycle distribution were calculated from a
sample of 5000 events.studied. These results suggested that SAHA not only
increased histone acetylation, as shown in H4 (Fig. 4A),
but also increased histone protein levels in TM10 and
TM2H cells (Fig. 4B). The increases in protein and acety-
lation levels of H3 and H4 in SAHA treated TM10 and
TM2H cell lines were indicated by the strong staining with
the acetylation specific antibodies of H3 and H4, while the
acetylated slow migrated isoforms showed smearing due
to the increases in their protein level (Fig. 5B). We did not,
however, observe differences in the initial acetylation
levels between untreated TM10 and TM2H cell lines.
SAHA induced hypophosphorylation of all the three
pocket proteins
Phosphorylation of three major pocket proteins, Rb, p107
and Rb2/p130, were examined after SAHA treatment, as
each pocket protein affects the G1 and S phases of the
cell cycle. Upon treatment with 2.5mM SAHA for 24h, a
profound increase in hypophosphorylation of the three
pocket proteins was observed in both TM10 and to a
lesser extent in TM2H cells as compared with their control
counterparts, judged by the faster mobility of the Rb
pocket protein isoforms on SDS gel (Fig. 5). The differ-
ence in the level of hypophosphorylated pRb pocket
protein isoforms between the two cell lines treated with
SAHA may be attributed to differences in G1 and S phase
cdk activity (examined in the following section). Results
suggested that SAHA induced cell growth arrest through
dephosphorylation of three pRb pocket proteins, which
may be related to inhibition in G1/S phase cdk activities.
SAHA inhibits multiple cyclin-associated kinase activities
There are extensive studies on the relation between
specific phosphorylation sites on pRb and its potential
Available online http://breast-cancer-research.com/content/3/2/122
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Figure 3
Effect of SAHA on TM10 and TM2H morphology. Bright field pictures
for living TM10 and TM2H cells at control and in SAHA treated
conditions for 24 h taken at 40× magnification.
Figure 4
Effect of SAHA on histone protein and acetylation levels. (A) Equal
amounts of isolated and purified histone samples from TM10 and
TM2H nuclei at control (C) and treated with 2.5 mM SAHA for 24 h (T)
were resolved on 15% acid–urea gel and stained with Coomassie
Blue. (B) Western blot analyses of the same samples in (A) were
analyzed, using 15% acid–urea gel, equilibrated to be transferred on
nitrocellulose membrane, probed first with anti-H3 polyclonal antibody,
striped and re-probed with anti-H4 polyclonal antibodies. Acetylated
histone H4 of multiple bands (arrows) was revealed as slow migrating
bands in treated versus control samples after Coomassie blue staining,
while H3 showed smear of the bands attributed to an increase in both
acetylation and protein synthesis. The increase in histones H3 and H4
protein and acetylation levels showed intense smeared bands after
alkaline phosphatase colorimetric reaction.
Figure 5
Effect of SAHA on phosphorylation levels of the pRb pocket proteins.
Western blot analysis of 100 mg nuclear protein extracts of TM10 and
TM2H cell lines in control (C) or treated with 2.5 mM SAHA for 24 h
(T). Protein samples were resolved by 10% SDS-PAGE, transferred
onto nitrocellulose membrane, blocked and probed with antibodies
against pRb, p107 and Rb-2/p130 as described in Materials and
methods. Note the fast migrating and more intense Rb, p107 and Rb-
2/p130 ‘hypophosphorylated forms’ in SAHA treated (T) versus
control (C) cell lines.transcription repression [32–34]. It is well known that pRb
phosphorylation sites are recognized by specific cdks
[33], and that most of the 16 pRb-phosphorylation sites
are sequentially phosphorylated throughout the cell cycle
(reviewed in [34,35]). SAHA treatment resulted in G1 cell
growth arrest in TM10 and TM2H cell lines, concomitant
with the profound increase in dephosphorylation of the
three pRb pocket proteins. Therefore, we examined cyclin
D1, E and A cdk2 activities in TM10 and TM2H cell cul-
tures after 24h treatment with SAHA because they reflect
kinase activities before, during and after the G1®S
checkpoint, respectively. The three cyclin/cdk2 complexes
directly reflect the sequential events in DNA synthesis
[36]. The initial levels of cyclin D1, E and A associated
kinase activities were 3-, 2.5- and 4-fold higher in
untreated TM2H compared with TM10 cells, respectively
(Fig. 6A–C). These results were predicted based on their
differences in cell distribution throughout the cell cycle, as
appeared in the cell cycle profile analysis, and may reflect
the cell line differences in known p53 status. Cyclin D1, E
and A associated kinase activities decreased by four-,
four-, and fivefold, respectively, in TM10 cells compared
with control on SAHA treatment, whereas only cyclin D1
and A associated kinase activities decreased (2.2- and
2.6-fold, respectively) in SAHA treated TM2H cells com-
pared with control (Fig. 6). These data demonstrate that
SAHA inhibits multiple cdk activities, and the degree of
inhibition was more profound in TM10 verses TM2H cells.
Effect of SAHA on p21, PCNA, E2F-1 and E2F-4 proteins
as a function of cell growth inhibition
The difference in the protein level of p21/Cip1 between
TM10 and TM2H cell lines was predicted based on their
differences in p53 status (Fig. 7A). Perinuclear localization
of p21 was detected in only few TM2H cells (p53 null)
when both cell lines were immunostained for p21,
whereas p21 was localized in both cytoplasmic and
nuclear compartments in TM10 cells (p53 wt) (data not
shown). The p21 expression level decreased by 50% in
TM10 cells upon SAHA treatment (Fig. 7A). These results
suggest that SAHA inhibited DNA synthesis in the pres-
ence or absence of p21 protein.
PCNA [37] and E2F-1 [1,7] are two key mediators of the
G1®S transition and DNA synthesis. Because such reg-
ulatory proteins can be present at different levels and in
Breast Cancer Research    Vol 3 No 2 Said et al
Figure 6
Effect of SAHA on cyclin-associated kinase activities in TM10 and TM2H cells. Equal amounts of nuclear protein extracts (250 mg) from TM10 and
TM2H cells at control (C) and treated with 2.5 mM SAHA for 24 h (T) were immunoprecipitated with antibodies against anti-cyclin D1 (A), anti-
cyclin E (B) and anti-cyclin A (C) or with rabbit preimmune serum, followed by kinase activity assay, as described in Materials and methods. The
negative control in each panel was 250 mg protein extract from TM2H cells at control condition immunoprecipitated with rabbit preimmune serum.
The phosphorylated substrates, pRb and histone (H1), were scanned and quantitated densitometricaly using a phosphoimager analyzer.
Histograms represent arbitrary units of the phosphorylated substrates after subtracting the background and the negative control.Available online http://breast-cancer-research.com/content/3/2/122
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different molecular complexes in nuclei as compared with
the cytoplasm, separation of the two cellular compart-
ments allowed an assessment of the site(s) at which these
proteins exert their primary activity unimpeded by artifacts
that may result from intermixing the two compartments. In
the untreated cells, the cytoplasmic PCNA protein levels
in TM10 and TM2H cell lines were similar, but the level of
PCNA in the nuclear fraction was fourfold higher in TM2H
cells compared with TM10 cells (Fig. 7B). The effect of
SAHA was profound on the nuclear PCNA fraction in both
cell lines, but minimal on the cytoplasmic PCNA fraction.
The pronounced difference in the levels of PCNA in
growing versus arrested cells is in accordance with the
determinant role PCNA plays in DNA synthesis [37,38].
To further investigate the effect of SAHA on inhibition of
DNA synthesis, we examined E2F-1 as a key mediator for
G1®S transition and DNA synthesis. The initial nuclear
protein level of E2F-1 in the untreated TM2H cells was
4.8-fold higher compared with the TM10 cell line
(Fig. 7C). Nuclear E2F-1 protein was completely abol-
ished in TM10 cells after 24h of SAHA treatment, and
decreased 2.2-fold in TM2H cells (Fig. 7C). These results
demonstrate that SAHA treatment also inhibits E2F-1
protein levels.
It has been reported that expression of E2F-4 gene does
not change in relation to cell growth, although a modest
increase can sometimes be observed in growing cells
[39]. E2F-4 protein levels were examined in the nuclear
and cytoplasmic fractions in both cell lines with and
without SAHA, and the protein levels did not change upon
SAHA treatment in either fractions of either cell line
(Fig. 7D). It is noteworthy that the mechanism of SAHA in
G1 cell growth arrest may target the expression of specific
proteins involved in DNA synthesis as it inhibited E2F-1
and PCNA, but not E2F-4, suggesting that SAHA may
cause different levels of histone acetylation at distinct
regions of the genome.
Rb-2/p130 subcellular localization and interaction with
E2F-4 was examined in both cell lines in the absence
and presence of SAHA because Rb-2/p130 is an
important cytoplasmic partner of E2F-4 and is capable
of inducing nuclear localization of the complex upon cell
growth arrest and differentiation [40,41]. Immunostain-
ing analysis using monoclonal antibody specific for
pRb-2/p130 revealed that SAHA enhanced pRb-2/
p130 nuclear localization in both cell lines treated with
SAHA for 24h compared with their controls (Fig. 8A).
To examine whether the increase in hypophosphoryla-
tion of pRb-2/p130 (Fig. 5) and its nuclear localization
after SAHA treatment was associated with interaction to
E2F-4, equal amounts of nuclear protein extracts were
immunoprecipitated with antibodies against E2F-4 fol-
lowed by western blot analysis against pRb-2/p130
antibodies. Interestingly, the results revealed an
unequivocal increase in the nuclear pRb-2/p130 protein
level associated with E2F-4 in both cell lines treated
with SAHA (Fig. 8B). These intriguing results indicate
that the interaction of hypophosphorylated pRb-2/p130
with E2F-4 followed by enhancement in nuclear location
after SAHA treatment is a novel mechanism in SAHA-
mediating cell growth arrest.
Figure 7
Effect of SAHA on the subcellular distribution of p21/Cip, PCNA, E2F-
1 and E2F-4 in TM10 and TM2H cell lines. Equal amounts of nuclear
(nuc.) and cytoplasmic (cyt.) protein extracts (100 mg) from TM10 and
TM2H cells at control (C) and treated with 2.5 mM SAHA for 24 h (T)
were analyzed by western blot (W.B.) using anti-mouse p21 antibody
(A), mouse anti-PCNA antibody (B), rabbit anti-E2F-1 antibody (C) and
anti-E2F-4 antibody (D). Protein bands were scanned and quantitated
densitometricaly using a phosphoimager analyzer. Histograms
represent arbitrary units for each protein.Breast Cancer Research    Vol 3 No 2 Said et al
Discussion
In this study, we present novel data on the mechanism of
SAHA in cell growth arrest on two mouse mammary
epithelial cell lines, TM10 (p53 wt) and TM2H (p53 null).
SAHA was able to increase histone H3 and H4 protein
and acetylation levels, and caused a profound decrease in
the protein levels of key molecules, PCNA and E2F-1,
essential for DNA synthesis. Furthermore, SAHA signifi-
cantly enhanced the interaction of pRb-2/p130 to E2F-4
and the nuclear localization of the pRb-2/p130–E2F-4
complex. SAHA also resulted in the inhibition of G1/S
kinase activities and, consequently, hypophosphorylation
of the three pRb pocket proteins, which led to G1 cell
growth arrest and dramatic decreases in DNA synthesis in
both cell lines. TM10 cells continued to be inhibited for
4 days upon removing SAHA after 2 days of treatment,
whereas TM2H cells were able to recover their prolifera-
tion potentials. A summary of the differences in the molec-
ular status and cell cycle profile between TM10 and
TM2H cell lines before SAHA treatment are summarized in
Table 1. These differences in p21 protein and BrdU index
were predicted based on p53 status of these two cell
lines and are in parallel with other reports on mammary
tumors, where the absence of p53 results primarily in
greater proliferation response in the affected cell [42]. No
differences in histone H3 and H4 acetylation levels were,
however, observed in relation to p53 status between the
two cell lines. It is not known at this point whether specific
mutations of p53 alter the degree of histone acetylation in
cells. Histone acetylation and p53 mutation appear not to
be correlated in this study; nevertheless, it is necessary
and more sensitive to examine histone acetylase and
deacetylase activities in correlation to p53 status.
The mechanism of SAHA in blocking DNA synthesis, as
demonstrated by flow cytometric analysis, appeared similar
in both TM10 and TM2H cell lines, and implicated several
events. First, SAHA increased histones H3 and H4 protein
levels after 24h of treatment, which could result in cell
cycle arrest. It has been reported that upregulation of
KIAA0128 gene expression, which has been implicated in
activation of histone mRNA synthesis, was related to cell
cycle arrest in MCF-7 cells after treatment with SAHA [43].
As SAHA treatment increased histone (H3 and H4) protein
and acetylation levels in both cell lines, this may have
altered the association of histones with DNA, thereby alter-
ing nucleosomal conformation and stability [27,44]. Local
perturbations of chromatin structure can specifically affect
the accessibility and/or function of transcriptional regula-
tory proteins that bind DNA sequences in the region where
histone acetylation or deacetylation took place [44]. HDAC
inhibitors, such as trichostatin A and trapoxin, modulate
gene expression in either a positive, negative or neutral
fashion [45]. Ample studies have demonstrated the impli-
cation of histone hyperacetylation in gene transcription but
also in silencing gene expression of others [27,44,45].
Table 1
The differences between TM10 and TM2H cell lines in the cell
cycle profile and protein status
TM10 cell line TM2H cell line
(p53 wt) (p53 null)
Nuclear proteins
E2F-1 1 4.8
PCNA 1 4.0
Rb-2/p130 1 (predominantly 1 (predominantly
hypophosphorylation) hypophosphorylation)
p21/Cip1 Strongly detectable  Weakly detectable
Cyclin-dependent kinase activity
D1 1 2.2
E 1 1.7
A1 3
BrdU index 16% 34%
Cell cycle profile
G0/G1 57% 39%
S 18% 28%
The numbers represent fold differences between the two cell lines with
the lower level designated as unity (eg 1).
Figure 8
Analysis of Rb-2/p130 subcellular localization and interaction with
E2F-4 in control and SAHA treated TM10 and TM2H cell lines. (A)
Immunofluorescent staining of Rb-2/p130 in TM10 and TM2H cell
lines at control (C) and treated with 2.5 mM SAHA for 24 h (T). (B)
Nuclear protein extracts (200 mg) of both cell lines and at the same
conditions as (A) were immunoprecipitated with anti-E2F-4 polyclonal
antibody followed by immunoblotting with mouse anti-Rb-2/p130
monoclonal antibody. I.P., immunoprecipitation; W.B., western blot.It is well known that E2F-1 regulates transcription of
genes predominantly expressed during the G1®S transi-
tion such as cyclins [1,5], cdks [1], E2F-1 gene [46], the
RB1 tumor suppressor gene [8,47], and genes for DNA
replication and repair enzymes and factors [4]. It appears
that SAHA has a profound inhibitory impact on the protein
levels of key molecules, E2F-1, PCNA and p21, essential
for DNA synthesis. Based on previous reports, disintegra-
tion of the cyclin/cdk complexes important for DNA syn-
thesis is correlated to E2F-1 expression level [1,5]. It is
thus conceivable to interpret that the profound inhibition in
E2F-1 and PCNA protein levels after 24h of exposure to
2.5mM SAHA may result in disintegration and deactivation
of D1, E and A cdk2 complexes, which consequently
leads to hypophosphorylation of the three Rb pocket pro-
teins. It is plausible to suggest that the inhibition in E2F-1
protein levels by SAHA was either at the transcription level
or induction of the ubiquitin-protein ligase responsible for
E2F-1 degradation, but not E2F-4, and this resulted in
blocked DNA synthesis. Further work is necessary to
prove whether the effect of SAHA is at the RNA transcrip-
tion level or on stability of E2F-1 protein.
The inhibition in nuclear p21 in SAHA treated TM2H as
well as TM10 cells underscores that SAHA-arrested cell
growth is through a p53-independent pathway. A recent
report indicated that the transcription of p21Cip1 and accu-
mulation of acetylated histones associated with the pro-
moter and coding regions of that gene were induced after
2h in 7.5mM SAHA and fall by 24h in T24 bladder carci-
noma cells [48]. Although we have utilized 2.5mM SAHA,
our results are in agreement with their data on the fall in
p21 level after 24h of treatment.
A more intriguing and novel mechanism of SAHA-medi-
ated cell growth arrest was the enhanced interaction and
nuclear localization of Rb-2/p130–E2F-4 complexes in
both cell lines after 24h of treatment. It is well docu-
mented that E2F-1 possesses an intrinsic nuclear localiza-
tion signal whereas E2F-4 is devoid of such signal
[49,50], and that the mechanism of E2F-4 nuclear local-
ization has been documented to be through its interaction
with Rb-2/p130 pocket protein, which impedes cell cycle
progression [39,40]. Furthermore, recent studies demon-
strated that Rb-2/p130 in complexes with E2F-4 actively
represses E2F-1 transcription in cell differentiation and
growth arrest, and that this complex was considered the
main E2F-1 regulator during the early G1 phase
[39,51,52]. Other reports suggest that Rb recruitment of
HDAC1 activity repressed E2F-1 [12,13]. Although SAHA
increases acetylation of histones H3 and H4, it is not
known whether SAHA is able to inhibit all HDAC activities
of all types of histones, including HDAC1, or whether the
profound increase in Rb-2/p130–E2F-4 nuclear complex
after SAHA treatment may have an alternative pathway
other than recruitment of HDAC1 activity.
The difference between TM10 (p53 wt) and TM2H
(p53 null) cell cultures in response to removing 2.5mM
SAHA following 2 or 3 days of treatment was significant.
We suggest that it might reflect their difference in p53
status. The TM10 cells did not exhibit signs of cell prolifer-
ation or ‘recovery’ during the following 3–4 days. TM2H
cells, in contrast, recovered by 88% after 2 days of treat-
ment. Longer treatment may be necessary to inhibit TM2H
(p53 null) mammary epithelial cells as preliminary results
indicate TM2H cells did not recover after 3 days of SAHA
treatment (data not shown). We suggest that the differ-
ence in growth recovery between TM10 (p53 wt) and
TM2H (p53 null) cell lines after 2 days in 2.5mM SAHA
may be attributed to two factors, both related to their p53
status. Firstly, the p53 in TM10 (p53 wt) cells might have
been acetylated upon treatment with 2.5mM SAHA for
2 or 3 days. Recent studies demonstrated acetylation of
p53 in the C-terminal domain increased the DNA-binding
capacity of the protein [53–55]. This event is obviously
not present in TM2H (p53 null). Secondly, although TM10
cells (p53 wt) have lost 64% of their nuclear p21 during
SAHA treatment, the remaining 36% of the nuclear p21
plus the continued synthesis of p21 by p53 activity
[55–57] during the recovery period would maintain TM10
cells in the inhibited state for several days without SAHA.
TM2H cells (p53 null), in contrast, lack both negative reg-
ulatory potentials of acetylated p53 and the availability of
nuclear p21.
We conclude that the mechanisms of SAHA inhibition of
DNA synthesis and cell growth arrest at G1 were similar in
both TM10 (p53 wt) and TM2H (p53 null) mouse
mammary epithelial cell lines. A proposed mechanism of
SAHA stresses the involvement of pRb-2/p130–E2F-4
interaction and nuclear localization, which ultimately
results in cell growth arrest and repression in nuclear
E2F-1 and PCNA protein levels, and the subsequent inhi-
bition of DNA synthesis in both cell lines. However, p53
status was critical in maintaining growth arrest in TM10
cells 4 days after removing SAHA treatment, whereas
TM2H cells (p53 null) recovered growth arrest under the
same conditions. We therefore suggest that the dose and
time regimen for histone deacetylase inhibitors, such as
SAHA, may have to consider the p53 status of breast
cancers.
Acknowledgements
The authors gratefully acknowledge Dr Paul A Marks and Dr Victoria M
Richon for providing us with the SAHA compound, Dr Sharon Roth for
help and advice with analysis of histone acetylation level and the anti-
H3 antibody, and Harry Thomas for the technical efforts on the histone
acetylation experiments. This work was supported by NIH Grant
CA-11944 (to DM).
References
1. DeGregori J, Kowalik T, Nevins JR: Cellular targets for activation
by the E2F1 transcription factor include DNA synthesis- and
G1/S-regulatory genes. Mol Cell Biol 1995, 15:4215–4224.
Available online http://breast-cancer-research.com/content/3/2/122
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
hBreast Cancer Research    Vol 3 No 2 Said et al
2. Shan B, Farmer AA, Lee WH: The molecular basis of E2F-
1/DP-1-induced S-phase entry and apoptosis. Cell Growth
Diff 1996,  7:689–697.
3. Cao L, Faha B, Dembski M, Tsai L, Harlow E, Dyson N: Indepen-
dent binding of retinoblastoma protein and p107 to the tran-
scription factors E2F. Nature (London) 1992, 355:176–179.
4. Hsiao K-M, McMahon SL, Farnham PJ: Multiple DNA elements
are required for the growth regulation of the mouse E2F1 pro-
motor. Genes Dev 1994, 8:1526–1537.
5. Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J,
Helin K, Jansen-Durr P, Henglein B: Cell cycle regulation of the
cyclin A gene promoter is mediated by a variant E2F site. Proc
Natl Acad Sci USA 1995, 92:11264–11268.
6. Nevins J: Toward an understanding of the functional complex-
ity of the E2F and retinoblastoma families. Cell Growth Diff
1998, 9:585–593.
7. Kel OV, Kel AE: Complex gene network in cell cycle regulation:
central role of the E2F family of transcription factors. Mol Biol
1997, 31:656–670.
8. Shan B, Chang CY, Jones D, Lee WH: The transcription factor
E2F-1 mediates the autoregulation of RB gene expression.
Mol Cell Biol 1994, 14:299–309.
9. Pierce AM, Schneider-Broussard, R, Philhower JL, Johnson DG:
Differential activities of E2F family members: unique functions
in regulating transcription. Mol Carcinogen 1998, 22:190–198.
10. Hurford RK Jr, Cobrinik D, Lee M-H, Dyson N: pRB and
p107/p130 are required for the regulated expression of dif-
ferent sets of E2F responsive genes. Genes Dev 1997, 11:
1447–1463.
11. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ,
Kouzarides T: Retinoblastoma protein recruits histone deacety-
lase to repress transcription. Nature 1998, 391:597–601.
12. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S,
Le Villain JP, Troalen F, Trouche D, Harel-Bellan A: Retinoblas-
toma protein represses transcription by recruiting a histone
deacetylase. Nature 1998, 391:601–604.
13. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D:
The three members of the pocket protein family share the
ability to repress E2F activity through recruitment of a histone
deacetylase. Proc Natl Acad Sci USA 1998, 95:10493–10498.
14. Luo RX, Postigo AA, Dean DC: Rb interacts with histone
deacetylase to repress transcription. Cell 1998, 92:463–473.
15. Lea MA, Randolph VM: Induction of reporter gene expression
by inhibitors of histone deacetylase. Anticancer Res 1998, 18:
2717–2722.
16. Archer SY, Meng S, Shei A, Hodin RA: p21WAF1 is required for
butyrate-mediated growth inhibition of human colon cancer
cells. Proc Natl Acad Sci USA 1998, 95:6791–6796.
17. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA,
Marks PA: A class of hybrid polar inducers of transformed cell
differentiation inhibits histone deacetylases. Proc Natl Acad
Sci USA 1998, 95:3003–3007.
18. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L,
Civoli F, Breslow R, Rifkind RA, Marks PA: Second generation
hybrid polar compounds are potent inducers of transformed
cell differentiation. Proc Natl Acad Sci USA 1996, 93:5705–
5708.
19. Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM,
Rifkind RA, Marks PA, Michaeli J: Hexamethylene bisacetamide
induces programmed cell death (apoptosis) and down-regu-
lates BCL-2 expression in human myeloma cells. Proc Natl
Acad Sci USA 1998, 95:162–166.
20. Richon VM, Russo P, Venta-Perez G, Cordon-Cardo C, Rifkind
RA, Marks PA: Two cytodifferentiation agent-induced path-
ways, differentiation and apoptosis, are distinguished by the
expression of human papillomavirus 16 E7 in human bladder
carcinoma cells. Cancer Res 1997, 57:2789–2798.
21. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff
H, Ervin T, Kufe D, Rifkind RA, Marks PA: Hexamethylene bisac-
etamide in myelodysplastic syndrome and acute myeloge-
nous leukemia: a phase II clinical trial with a differentiation
inducing agent. Blood 1992, 80:2604–2609.
22. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM:
Chemoprevention of carcinogen-induced mammary tumori-
genesis by the hybrid polar cytodifferentiation agent,
suberaniohydroxamic acid (SAHA). Anticancer Res 1999,
19:4999–5005.
23. Medina D, Kittrell FS, Oborn CJ, Schwartz M: Growth factor
dependency and gene expression in preneoplastic mouse
mammary epithelial cells. Cancer Res 1993, 53:668–674.
24. Jerry DJ, Ozbun MA, Kittrell FS, Lane DP, Medina D, Butel JS:
Mutations in p53 are frequent in the preneoplastic stage of
mouse mammary tumor development. Cancer Res 1993, 53:
3374–3381.
25. Said TK, Medina D: Interaction of retinoblastoma protein and D
cyclins during cell-growth inhibition by hexamethyl-
enebisamide in TM2H mouse epithelial cells. Mol Carcinogen
1998, 22:128–143.
26. Edmondson DG, Roth SY: Interactions of transcriptional regu-
lators with histones. Methods 1998, 15:355–364.
27. Roth SY, Allis CD: Histone acetylation and chromatin assem-
bly — a single escort, multiple dances. Cell 1996, 87:5–8.
28. Said TK, Medina D: Cell cyclins and cyclin-dependent kinase
activities in mouse mammary tumor development. Carcino-
genesis 1995,  16:823–830.
29. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of
apoptotic program in cell-free extracts: requirement for dATP
and cytochrome C. Cell 1996, 86: 147–157.
30. Medina D: Preneoplasia in mammary tumorigenesis. In
Mammary Tumor Cell Cycle, Differentiation and Metastases,
Advances in Cellular and Molecular Biology of Breast Cancer.
Edited by Dickson RB, Lippman ME. Norwell, MA: Kluwer Acade-
mic Publishers, 1996:37–69.
31. O’Keefe RT, Henderson SC, Spector DL: Dynamic organization
of DNA replication in mammalian cell nuclei: spatially and
temporally defined replication of chromosome-specific alpha-
satellite DNA sequences. J Cell Biol 1992, 116:1095–1110.
32. Harbour WJ, Luo RX, Dei Santi A, Postigo AA, Dean DC: Cdk
phosphorylation triggers sequential intramolecular interac-
tions that progressively block Rb functions as cells move
through G1. Cell 1999, 98:859–869.
33. Zarkowska T, Mittnacht S: Differential phosphorylation of the
retinoblastaoma protein by G1/S cyclin-dependent kinases. J
Biol Chem 1997, 272:12738–12746.
34. Lundberg AS, Weinberg RA: Functional interaction of
retinoblastoma protein requires sequential modification by at
least two distinct cyclin–cdk complexes. Mol Cell Biol 1998,
18:753–761.
35. Weinberg RA: The retinoblastoma protein and cell cycle
control.  Cell 1995,  81:323–330.
36. Sherr CJ: G1 phase progression: cycling on cue. Cell 1994, 79:
551–555.
37. Jonsson ZO, Hubscher U: Proliferating cell nuclear antigen:
more than a clamp for DNA polymerases. BioEssays 1997,
19:967–975.
38. Jonsson ZJ, Hindges R, Hubscher U: Regulation of DNA replica-
tion and repair proteins through interaction with the front side
of proliferating cell nuclear antigen. EMBO J 1998, 17:
2412–2425.
39. Moberg K, Starz MA, Lees JA: E2F-4 switches from p130 to
p107 and pRb in response to cell cycle reentry. Mol Cell Biol
1996, 16:1436–1449.
40. Puri PL, Cimino L, Fulco M, Zimmerman C, La Thangue NB, Gior-
dano A, Graessmann A, Levrero M: Regulation of E2F4 mito-
genic activity during terminal differentiation by its
heterodimerization partners for nuclear translocation. Cancer
Res 1998, 58:1325–1331.
41. Smith EJ, Leone G, DeGregori J, Jakoi L, Nevins J: The accumu-
lation of an E2F-p130 transcriptional repressor distinguishes
a G0 cell state from a G1 cell state. Mol Cell Biol 1996,
16:6965–6976.
42. O’Connor PM, Lam EW-F, Griffin S, Zhong S, Leighton LC, Bur-
bidge SA, Lu X: Physical and functional interactions between
p53 and cell cycle co-operating transcription factors, E2F1
and DP1. EMBO J 1995, 14:6184–6192.
43. Melichar H, Bosch I, Molnar GM, Huang L, Pardee AB: Detec-
tion of eukaryotic cDNA in differential display is enhanced
by the addition of E. coli RNA. Biotechniques 2000, 28:76–
82.
44. Struhl K: Histone acetylation and transcriptional regulatory
mechanisms.  Gene Dev 1998, 12:599–606.
45. Lint CV, Emiliani S, Verdin E: The expression of a small fraction
of cellular genes is changed in response to histone hyper-
acetylation. Gene Expression 1996, 5:245–253.Available online http://breast-cancer-research.com/content/3/2/122
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
46. Johnson DG, Ohtani K, Nevins JR: Autoregulatory control of
E2F1 expression in response to positive and negative regula-
tors of cell cycle progression. Gene Dev 1994, 8:1514–1525.
47. Zhu L, Xie E, Chang LS: Differential roles of two tandem E2F
sites in repression of the human p107 promoter by retino-
blastoma and p107 proteins. Mol Cell Biol 1995, 15:3552–
3562.
48. Richon VM, Sandhoff, TW, Rifkind RA, Marks PA: Histone
deacetylase inhibitor selectively induces p21WAF1 expression
and gene-associated histone acetylation. Progr Natl Assoc Sci
2000, 97:10014–10019.
49. De la Luna S, Burden MJ, Lee C-W, La Thangue NB: Nuclear
accumulation of the E2F heterodimer regulated by subunit
composition and alternative splicing of a nuclear localization
signal. J Cell Sci 1996, 109:2443–2452.
50. Magae J, Wu C-L, Illenye S, Harlow E, Heintz NH: Nuclear local-
ization of DP and E2F transcription factors by heterodimeric
partners and retinoblastoma protein family members. J Cell
Sci 1996, 109:1717–1726.
51. Ikeda M-A, Jakoi L, Nevins JR: A unique role for the Rb protein
in controlling E2F accumulation during cell growth and differ-
entiation. Proc Natl Acad Sci USA 1996, 93:3215–3220.
52. Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA: Cell
cycle-specific association of E2F with the p130 E1A-binding
protein. Gene Dev 1993, 7:2392–2404.
53. Gu W, Roeder RG: Activation of p53 sequence-specific DNA
binding by acetylation of the p53 C-terminal domain. Cell
1997,  90:595–606.
54. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A,
Anderson CW, Appella E: DNA damage activates p53 through
a phosphorylation-acetylation cascade. Gene Dev 1998,
12:2831–2841.
55. Chiarugi V, Cinelli M, Magnelli L: Acetylation and phosphoryla-
tion of the carboxy-terminal domain of p53: regulative signifi-
cance. Oncol Res 1998, 10:55–57.
56. Weiss RH Randour CJ: The permissive effect of
p21(Waf1/Cip1) on DNA synthesis is dependent on cell type.
Effect is absent in p53-inactive cells. Cell Signal 2000,
12:413–418.
57. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makuuchi M: Reduced
p21(WAF1/Cip1) protein expression is predominantly related
to altered p53 in hepatocellular carcinomas. Br J Cancer
2000,  83:50–55.